Ludwig Keilholz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ludwig Keilholz has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
R Sauer
6 shared publications- Udo Sebastian Gaipl
Translational Radiobiology, Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg
4 shared publications - Benjamin Frey
Translational Radiobiology, Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg
3 shared publications M H Seegenschmiedt
3 shared publications- Oliver Josef Ott
Strahlenklinik, Universitätsklinikum Erlangen, Erlangen, Deutschland
2 shared publications R Schulz-Wendtland
2 shared publications
Latest Publications
- Open Access
- 14 August 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (16) , 5854
Low Dose Radiation Therapy, Particularly with 0.5 Gy, Improves Pain in Degenerative Joint Disease of the Fingers: Results of a Retrospective Analysis
Low-dose radiation therapy (LDRT) has been successfully established for decades as an alternative analgesic treatment option for patients suffering from chronic degenerative and inflammatory diseases. In this study, 483 patients were undergoing LDRT for degenerative joint disease of the fingers and thumb at the University Hospital Erlangen between 2004 and 2019. Radiotherapy was applied according to the German guidelines for LDRT. Several impact factors on therapeutic success, such as the age and gender, the number of affected fingers, the single and cumulative dose, as well as the number of series, were investigated. In summary, 70% of the patients showed an improvement of their pain following LDRT. No significant impact was found for the factors age, gender, the number of series or the cumulative dosage. Patients with an involvement of the thumb showed a significantly worse outcome compared to patients with an isolated affection of the fingers. In this cohort, patients receiving a single dose of 0.5 Gy reported a significantly better outcome than patients receiving 1.0 Gy, strongly suggesting a reduction in the total dose. In summary, LDRT is a good alternative treatment option for patients suffering from degenerative and inflammatory joint disease of the fingers.
- 14 August 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (16) , 5854
Open AccessLow Dose Radiation Therapy, Particularly with 0.5 Gy, Improves Pain in Degenerative Joint Disease of the Fingers: Results of a Retrospective Analysis
Low-dose radiation therapy (LDRT) has been successfully established for decades as an alternative analgesic treatment option for patients suffering from chronic degenerative and inflammatory diseases. In this study, 483 patients were undergoing LDRT for degenerative joint disease of the fingers and thumb at the University Hospital Erlangen between 2004 and 2019. Radiotherapy was applied according to the German guidelines for LDRT. Several impact factors on therapeutic success, such as the age and gender, the number of affected fingers, the single and cumulative dose, as well as the number of series, were investigated. In summary, 70% of the patients showed an improvement of their pain following LDRT. No significant impact was found for the factors age, gender, the number of series or the cumulative dosage. Patients with an involvement of the thumb showed a significantly worse outcome compared to patients with an isolated affection of the fingers. In this cohort, patients receiving a single dose of 0.5 Gy reported a significantly better outcome than patients receiving 1.0 Gy, strongly suggesting a reduction in the total dose. In summary, LDRT is a good alternative treatment option for patients suffering from degenerative and inflammatory joint disease of the fingers.
- 16 October 2013
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 190 (1) , 17-25
Time management in radiation oncology: evaluation of time, attendance of medical staff, and resources during radiotherapy for prostate cancer
In order to evaluate resource requirements, the German Society of Radiation Oncology (DEGRO) recorded the times needed for core procedures in the radio-oncological treatment of various cancer types within the scope of its QUIRO trial. The present study investigated the personnel and infrastructural resources required in radiotherapy of prostate cancer. The investigation was carried out in the setting of definitive radiotherapy of prostate cancer patients between July and October 2008 at two radiotherapy centers, both with well-trained staff and modern technical facilities at their disposal. Personnel attendance times and room occupancy times required for core procedures (modules) were each measured prospectively by two independently trained observers using time measurements differentiated on the basis of professional group (physician, physicist, and technician), 3D conformal (3D-cRT), and intensity-modulated radiotherapy (IMRT). Total time requirements of 983 min for 3D-cRT and 1485 min for step-and-shoot IMRT were measured for the technician (in terms of professional group) in all modules recorded and over the entire course of radiotherapy for prostate cancer (72–76 Gy). Times needed for the medical specialist/physician were 255 min (3D-cRT) and 271 min (IMRT), times of the physicist were 181 min (3D-cRT) and 213 min (IMRT). The difference in time was significant, although variations in time spans occurred primarily as a result of various problems during patient treatment. This investigation has permitted, for the first time, a realistic estimation of average personnel and infrastructural requirements for core procedures in quality-assured definitive radiotherapy of prostate cancer. The increased time needed for IMRT applies to the step-and-shoot procedure with verification measurements for each irradiation planning. Zur Evaluation des Ressourcenverbrauchs führte die Deutsche Gesellschaft für Radioonkologie (DEGRO) im Rahmen der QUIRO-Studien an unterschiedlichen Karzinomen eine Zeiterfassung für die wichtigsten Kernprozesse in der Radioonkologie durch. In dieser Arbeit wurden die notwendigen personellen und räumlichen Ressourcen bei der Bestrahlung des Prostatakarzinoms untersucht. Die Untersuchung bei der definitiven Strahlenbehandlung von Patienten mit Prostatakarzinomen erfolgte an zwei personell gut und technisch modern ausgestatteten Radiotherapiezentren zwischen Juli und Oktober 2008. Die zeitliche Erfassung von Personalbindungs- und Raumbelegungszeiten für wesentliche Arbeitsschritte/Module wurde prospektiv durch jeweils zwei unabhängige geschulte Untersucher mit Zeitmessungen differenziert nach Berufsgruppen [Arzt, Physiker und Medizinisch-technische Assistenten im Fachbereich Radiologie (MTAR)] sowie nach 3-D-konformaler- (3D-cRT) und intensitätsmodulierter Radiotherapie (IMRT) durchgeführt. Bei der Strahlenbehandlung des Prostatakarzinoms zeigt sich über alle erfassten Module und die gesamte Bestrahlungsserie (72–76 Gy) eine zeitliche Gesamtbelastung der MTAR (als Berufsgruppe) von 983 min bei einer 3D-cRT beziehungsweise 1485 min bei einer „Step-and-shoot“-IMRT Bestrahlung. Der Zeitaufwand für den Facharzt lag bei 255 (3D-cRT) und 271 min (IMRT) sowie für den Physiker bei 181 (3D-cRT) und 213 min (IMRT). Der zeitliche Unterschied war signifikant, wobei Schwankungen in den Zeitspannen vor allem durch unterschiedliche Probleme bei der Behandlung der Patienten auftraten. Durch die Untersuchung ist es erstmals möglich, eine realistische Abschätzung des durchschnittlichen Personal- und Raumbedarfs für die Kernprozesse einer qualitätsgesicherten definitiven Strahlentherapie des Prostatakarzinoms zu erhalten. Der erhöhte Zeitbedarf für eine IMRT gilt hier für das „Step-and-shoot“-Verfahren mit Verifikationsmessungen jedes Bestrahlungsplans.
- 16 October 2013
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 190 (1) , 17-25
Time management in radiation oncology: evaluation of time, attendance of medical staff, and resources during radiotherapy for prostate cancer
In order to evaluate resource requirements, the German Society of Radiation Oncology (DEGRO) recorded the times needed for core procedures in the radio-oncological treatment of various cancer types within the scope of its QUIRO trial. The present study investigated the personnel and infrastructural resources required in radiotherapy of prostate cancer. The investigation was carried out in the setting of definitive radiotherapy of prostate cancer patients between July and October 2008 at two radiotherapy centers, both with well-trained staff and modern technical facilities at their disposal. Personnel attendance times and room occupancy times required for core procedures (modules) were each measured prospectively by two independently trained observers using time measurements differentiated on the basis of professional group (physician, physicist, and technician), 3D conformal (3D-cRT), and intensity-modulated radiotherapy (IMRT). Total time requirements of 983 min for 3D-cRT and 1485 min for step-and-shoot IMRT were measured for the technician (in terms of professional group) in all modules recorded and over the entire course of radiotherapy for prostate cancer (72–76 Gy). Times needed for the medical specialist/physician were 255 min (3D-cRT) and 271 min (IMRT), times of the physicist were 181 min (3D-cRT) and 213 min (IMRT). The difference in time was significant, although variations in time spans occurred primarily as a result of various problems during patient treatment. This investigation has permitted, for the first time, a realistic estimation of average personnel and infrastructural requirements for core procedures in quality-assured definitive radiotherapy of prostate cancer. The increased time needed for IMRT applies to the step-and-shoot procedure with verification measurements for each irradiation planning. Zur Evaluation des Ressourcenverbrauchs führte die Deutsche Gesellschaft für Radioonkologie (DEGRO) im Rahmen der QUIRO-Studien an unterschiedlichen Karzinomen eine Zeiterfassung für die wichtigsten Kernprozesse in der Radioonkologie durch. In dieser Arbeit wurden die notwendigen personellen und räumlichen Ressourcen bei der Bestrahlung des Prostatakarzinoms untersucht. Die Untersuchung bei der definitiven Strahlenbehandlung von Patienten mit Prostatakarzinomen erfolgte an zwei personell gut und technisch modern ausgestatteten Radiotherapiezentren zwischen Juli und Oktober 2008. Die zeitliche Erfassung von Personalbindungs- und Raumbelegungszeiten für wesentliche Arbeitsschritte/Module wurde prospektiv durch jeweils zwei unabhängige geschulte Untersucher mit Zeitmessungen differenziert nach Berufsgruppen [Arzt, Physiker und Medizinisch-technische Assistenten im Fachbereich Radiologie (MTAR)] sowie nach 3-D-konformaler- (3D-cRT) und intensitätsmodulierter Radiotherapie (IMRT) durchgeführt. Bei der Strahlenbehandlung des Prostatakarzinoms zeigt sich über alle erfassten Module und die gesamte Bestrahlungsserie (72–76 Gy) eine zeitliche Gesamtbelastung der MTAR (als Berufsgruppe) von 983 min bei einer 3D-cRT beziehungsweise 1485 min bei einer „Step-and-shoot“-IMRT Bestrahlung. Der Zeitaufwand für den Facharzt lag bei 255 (3D-cRT) und 271 min (IMRT) sowie für den Physiker bei 181 (3D-cRT) und 213 min (IMRT). Der zeitliche Unterschied war signifikant, wobei Schwankungen in den Zeitspannen vor allem durch unterschiedliche Probleme bei der Behandlung der Patienten auftraten. Durch die Untersuchung ist es erstmals möglich, eine realistische Abschätzung des durchschnittlichen Personal- und Raumbedarfs für die Kernprozesse einer qualitätsgesicherten definitiven Strahlentherapie des Prostatakarzinoms zu erhalten. Der erhöhte Zeitbedarf für eine IMRT gilt hier für das „Step-and-shoot“-Verfahren mit Verifikationsmessungen jedes Bestrahlungsplans.
- Open Access
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 2, 120
Immunomodulatory Properties and Molecular Effects in Inflammatory Diseases of Low-Dose X-Irradiation
Inflammatory diseases are the result of complex and pathologically unbalanced multicellular interactions. For decades, low-dose X-irradiation therapy (LD-RT) has been clinically documented to exert an anti-inflammatory effect on benign diseases and chronic degenerative disorders. By contrast, experimental studies to confirm the effectiveness and to reveal underlying cellular and molecular mechanisms are still at their early stages. During the last decade, however, the modulation of a multitude of immunological processes by LD-RT has been explored in vitro and in vivo. These include leukocyte/endothelial cell adhesion, adhesion molecule and cytokine/chemokine expression, apoptosis induction, and mononuclear/polymorphonuclear cell metabolism and activity. Interestingly, these mechanisms display comparable dose dependences and dose-effect relationships with a maximum effect in the range between 0.3 and 0.7 Gy, already empirically identified to be most effective in the clinical routine. This review summarizes data and models exploring the mechanisms underlying the immunomodulatory properties of LD-RT that may serve as a prerequisite for further systematic analyses to optimize low-dose irradiation procedures in future clinical practice.
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 2, 120
Open AccessImmunomodulatory Properties and Molecular Effects in Inflammatory Diseases of Low-Dose X-Irradiation
Inflammatory diseases are the result of complex and pathologically unbalanced multicellular interactions. For decades, low-dose X-irradiation therapy (LD-RT) has been clinically documented to exert an anti-inflammatory effect on benign diseases and chronic degenerative disorders. By contrast, experimental studies to confirm the effectiveness and to reveal underlying cellular and molecular mechanisms are still at their early stages. During the last decade, however, the modulation of a multitude of immunological processes by LD-RT has been explored in vitro and in vivo. These include leukocyte/endothelial cell adhesion, adhesion molecule and cytokine/chemokine expression, apoptosis induction, and mononuclear/polymorphonuclear cell metabolism and activity. Interestingly, these mechanisms display comparable dose dependences and dose-effect relationships with a maximum effect in the range between 0.3 and 0.7 Gy, already empirically identified to be most effective in the clinical routine. This review summarizes data and models exploring the mechanisms underlying the immunomodulatory properties of LD-RT that may serve as a prerequisite for further systematic analyses to optimize low-dose irradiation procedures in future clinical practice.
- Open Access
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 2, 75
How Does Ionizing Irradiation Contribute to the Induction of Anti-Tumor Immunity?
Radiotherapy (RT) with ionizing irradiation is commonly used to locally attack tumors. It induces a stop of cancer cell proliferation and finally leads to tumor cell death. During the last years it has become more and more evident that besides a timely and locally restricted radiation-induced immune suppression, a specific immune activation against the tumor and its metastases is achievable by rendering the tumor cells visible for immune attack. The immune system is involved in tumor control and we here outline how RT induces anti-inflammation when applied in low doses and contributes in higher doses to the induction of anti-tumor immunity. We especially focus on how local irradiation induces abscopal effects. The latter are partly mediated by a systemic activation of the immune system against the individual tumor cells. Dendritic cells are the key players in the initiation and regulation of adaptive anti-tumor immune responses. They have to take up tumor antigens and consecutively present tumor peptides in the presence of appropriate co-stimulation. We review how combinations of RT with further immune stimulators such as AnnexinA5 and hyperthermia foster the dendritic cell-mediated induction of anti-tumor immune responses and present reasonable combination schemes of standard tumor therapies with immune therapies. It can be concluded that RT leads to targeted killing of the tumor cells and additionally induces non-targeted systemic immune effects. Multimodal tumor treatments should therefore tend to induce immunogenic tumor cell death forms within a tumor microenvironment that stimulates immune cells.
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 2, 75
Open AccessHow Does Ionizing Irradiation Contribute to the Induction of Anti-Tumor Immunity?
Radiotherapy (RT) with ionizing irradiation is commonly used to locally attack tumors. It induces a stop of cancer cell proliferation and finally leads to tumor cell death. During the last years it has become more and more evident that besides a timely and locally restricted radiation-induced immune suppression, a specific immune activation against the tumor and its metastases is achievable by rendering the tumor cells visible for immune attack. The immune system is involved in tumor control and we here outline how RT induces anti-inflammation when applied in low doses and contributes in higher doses to the induction of anti-tumor immunity. We especially focus on how local irradiation induces abscopal effects. The latter are partly mediated by a systemic activation of the immune system against the individual tumor cells. Dendritic cells are the key players in the initiation and regulation of adaptive anti-tumor immune responses. They have to take up tumor antigens and consecutively present tumor peptides in the presence of appropriate co-stimulation. We review how combinations of RT with further immune stimulators such as AnnexinA5 and hyperthermia foster the dendritic cell-mediated induction of anti-tumor immune responses and present reasonable combination schemes of standard tumor therapies with immune therapies. It can be concluded that RT leads to targeted killing of the tumor cells and additionally induces non-targeted systemic immune effects. Multimodal tumor treatments should therefore tend to induce immunogenic tumor cell death forms within a tumor microenvironment that stimulates immune cells.
- 28 December 2009
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 186 (1) , 18-23
Calcifying Tendonitis of the Shoulder Joint
Background and Purpose: Calcifying tendonitis is a degenerative inflammatory joint disorder. Pain relief can be successfully achieved with low-dose radiotherapy. It is actually unknown which types of calcifying tendonitis respond to radiotherapy and which do not. The authors tried to get predictive objectives for the response to radiotherapy on the basis of different morphological patterns of calcifications evaluated by X-ray and ultrasound. Patients and Methods: Between August 1999 and September 2002, a total of 102 patients with 115 painful shoulder joints underwent low-dose radiotherapy. At the beginning of radiotherapy, every shoulder joint was examined with a radiograph in two planes. In addition, sonography was performed before and during therapy. This examination was repeated 6 and 18 months after irradiation. Radiotherapy consisted of two series with a total dose of 6.0 Gy. 29 joints with calcifying tendonitis could be further divided using the sonographic and radiographic classification according to Farin and Gärtner, respectively. Results: Pain relief was achieved in 94/115 joints (82%) at a follow-up of 18 months (median). A different response to radiotherapy was found using the sonographic classification of Farin: calcifying tendonitis type III (n = 18) responded well in contrast to a significantly worse result in type I (n = 11). The radiologic classification did not provide a predictive value. Conclusion: Sonographic classification of calcifying tendonitis is predictive for the outcome after radiotherapy. Especially patients with Farin type III calcification will benefit from low-dose radiotherapy.
- 28 December 2009
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 186 (1) , 18-23
Calcifying Tendonitis of the Shoulder Joint
Background and Purpose: Calcifying tendonitis is a degenerative inflammatory joint disorder. Pain relief can be successfully achieved with low-dose radiotherapy. It is actually unknown which types of calcifying tendonitis respond to radiotherapy and which do not. The authors tried to get predictive objectives for the response to radiotherapy on the basis of different morphological patterns of calcifications evaluated by X-ray and ultrasound. Patients and Methods: Between August 1999 and September 2002, a total of 102 patients with 115 painful shoulder joints underwent low-dose radiotherapy. At the beginning of radiotherapy, every shoulder joint was examined with a radiograph in two planes. In addition, sonography was performed before and during therapy. This examination was repeated 6 and 18 months after irradiation. Radiotherapy consisted of two series with a total dose of 6.0 Gy. 29 joints with calcifying tendonitis could be further divided using the sonographic and radiographic classification according to Farin and Gärtner, respectively. Results: Pain relief was achieved in 94/115 joints (82%) at a follow-up of 18 months (median). A different response to radiotherapy was found using the sonographic classification of Farin: calcifying tendonitis type III (n = 18) responded well in contrast to a significantly worse result in type I (n = 11). The radiologic classification did not provide a predictive value. Conclusion: Sonographic classification of calcifying tendonitis is predictive for the outcome after radiotherapy. Especially patients with Farin type III calcification will benefit from low-dose radiotherapy.
- 9 June 2009
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 185 (6) , 364-370
Effect of total mesorectal excision on the outcome of rectal cancer after standardized postoperative radiochemotherapy
Purpose: To compare local control, disease-free survival and overall survival after postoperative radiochemotherapy with or without total mesorectal excision (TME) in a retrospective analysis. Patients and Methods: Between 1993 and 2002, 103 patients with UICC stage II and III rectal cancer were treated by surgery and postoperative chemoradiation. Group B (n = 50; 1993–1998) were operated before TME era without using TME and group A (n = 53; 1998–2002) with TME; both groups received identical radiochemotherapy to a total dose of 50.4 Gy (median) and two courses of continuous 5-fluorouracil infusion. Results: Patients in group A (TME) showed a significant improvement in 5-year disease-free survival (71.1%; 46.8%) and freedom from distant metastases (76.3%; 46.9%) and a marked improvement of local control (85.2%; 62.5%). Acute and late toxicity were significantly less frequent in group A. Conclusion: Radiochemotherapy cannot compensate an insufficient surgical procedure. These data confirm that TME is the standard. High outcome quality can be achieved in daily practice compared to results of randomized studies without patient selection.
- 9 June 2009
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 185 (6) , 364-370
Effect of total mesorectal excision on the outcome of rectal cancer after standardized postoperative radiochemotherapy
Purpose: To compare local control, disease-free survival and overall survival after postoperative radiochemotherapy with or without total mesorectal excision (TME) in a retrospective analysis. Patients and Methods: Between 1993 and 2002, 103 patients with UICC stage II and III rectal cancer were treated by surgery and postoperative chemoradiation. Group B (n = 50; 1993–1998) were operated before TME era without using TME and group A (n = 53; 1998–2002) with TME; both groups received identical radiochemotherapy to a total dose of 50.4 Gy (median) and two courses of continuous 5-fluorouracil infusion. Results: Patients in group A (TME) showed a significant improvement in 5-year disease-free survival (71.1%; 46.8%) and freedom from distant metastases (76.3%; 46.9%) and a marked improvement of local control (85.2%; 62.5%). Acute and late toxicity were significantly less frequent in group A. Conclusion: Radiochemotherapy cannot compensate an insufficient surgical procedure. These data confirm that TME is the standard. High outcome quality can be achieved in daily practice compared to results of randomized studies without patient selection.
- 1 September 2000
- Vol. 76 (9)
UVB-irradiated T-cells undergoing apoptosis lose L-selectin by metalloprotese-mediated shedding.
- 1 September 2000
- Vol. 76 (9)
UVB-irradiated T-cells undergoing apoptosis lose L-selectin by metalloprotese-mediated shedding.
- 1 February 1998
- Vol. 174 (2)
[Effects of fractionation and dose rate in PDR brachytherapy of B14 cells].
- 1 February 1998
- Vol. 174 (2)
[Effects of fractionation and dose rate in PDR brachytherapy of B14 cells].
- 30 September 1997
- Published by Elsevier in European Journal of Cancer
- Vol. 33, S188
847: Iridium-192 brachytherapy (BT) in head & neck cancer (H&NSCC)
- 30 September 1997
- Published by Elsevier in European Journal of Cancer
- Vol. 33, S188
847: Iridium-192 brachytherapy (BT) in head & neck cancer (H&NSCC)
- 30 September 1997
- Published by Elsevier in European Journal of Cancer
- Vol. 33, S255
1153: Advanced primary and recurrent head and neck malignancies treated with interstitial thermo radiotherapy: 10-year results
- 30 September 1997
- Published by Elsevier in European Journal of Cancer
- Vol. 33, S255
1153: Advanced primary and recurrent head and neck malignancies treated with interstitial thermo radiotherapy: 10-year results